Chemistry
How Covalent Inhibitors Target Active Site Residues in Enzyme Inactivation
Quick fact
Some drugs like aspirin and penicillin are covalent inhibitors: they form a permanent chemical bond with a specific amino acid in the enzyme's active site, irreversibly disabling the enzyme. This is why they have long-lasting effects even after the drug is cleared from the bloodstream.
Why this is interesting
Imagine a drug that doesn't just block an enzyme for a few minutes, but permanently 'locks' it shut. How could a single chemical bond lead to such a lasting effect?
Read the full explanation
Understanding How Covalent Inhibitors Target Active Site Residues in Enzyme Inactivation
Unlike reversible inhibitors that bind and let go, covalent inhibitors form a chemical bond (covalent bond) with the enzyme. This typically happens when a reactive group on the inhibitor—an 'electrophilic warhead'—encounters a nucleophilic side chain in the enzyme's active site, such as the thiol of cysteine, the hydroxyl of serine, or the amino group of lysine. The reaction is often irreversible, permanently altering the enzyme's structure and function. Because the active site is where catalysis happens, this modification blocks substrate binding and catalysis itself.
A deeper explanation
Covalent inhibition is a two-step process: first, the inhibitor binds to the enzyme (often like a regular substrate), and second, it reacts to form a covalent adduct. The selectivity comes from the precise positioning of the electrophilic warhead relative to the nucleophilic residue in the active site. For example, aspirin acetylates a serine in COX enzymes, while penicillin reacts with a serine in bacterial transpeptidase, preventing cell wall synthesis. The rate of inactivation depends on both the reactivity of the warhead and its placement, but the result is a permanent loss of enzymatic activity. This mechanism is why covalent inhibitors can be extremely potent, but also why they pose a risk of off-target effects if related enzymes are modified.